4wrb: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Macrophage Migration Inhibitory Factor in complex with a biaryltriazole inhibitor (3b-190)== | ==Macrophage Migration Inhibitory Factor in complex with a biaryltriazole inhibitor (3b-190)== | ||
<StructureSection load='4wrb' size='340' side='right' caption='[[4wrb]], [[Resolution|resolution]] 1.81Å' scene=''> | <StructureSection load='4wrb' size='340' side='right' caption='[[4wrb]], [[Resolution|resolution]] 1.81Å' scene=''> | ||
| Line 5: | Line 6: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3TW:4-{4-[6-(2-METHOXYETHOXY)QUINOLIN-2-YL]-1H-1,2,3-TRIAZOL-1-YL}PHENOL'>3TW</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=IPA:ISOPROPYL+ALCOHOL'>IPA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3TW:4-{4-[6-(2-METHOXYETHOXY)QUINOLIN-2-YL]-1H-1,2,3-TRIAZOL-1-YL}PHENOL'>3TW</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=IPA:ISOPROPYL+ALCOHOL'>IPA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4wr8|4wr8]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4wr8|4wr8]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wrb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wrb OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4wrb RCSB], [http://www.ebi.ac.uk/pdbsum/4wrb PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wrb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wrb OCA], [http://pdbe.org/4wrb PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wrb RCSB], [http://www.ebi.ac.uk/pdbsum/4wrb PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4wrb ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
| Line 19: | Line 20: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 4wrb" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Macrophage inhibitory factor|Macrophage inhibitory factor]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 03:20, 26 January 2017
Macrophage Migration Inhibitory Factor in complex with a biaryltriazole inhibitor (3b-190)Macrophage Migration Inhibitory Factor in complex with a biaryltriazole inhibitor (3b-190)
Structural highlights
Disease[MIF_HUMAN] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Function[MIF_HUMAN] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.[1] [2] Publication Abstract from PubMedOptimization is reported for biaryltriazoles as inhibitors of the tautomerase activity of human macrophage migration inhibitory factor (MIF), a proinflammatory cytokine associated with numerous inflammatory diseases and cancer. A combined approach was taken featuring organic synthesis, enzymatic assaying, crystallography, and modeling including free-energy perturbation (FEP) calculations. X-ray crystal structures for 3a and 3b bound to MIF are reported and provided a basis for the modeling efforts. The accommodation of the inhibitors in the binding site is striking with multiple hydrogen bonds and aryl-aryl interactions. Additional modeling encouraged pursuit of 5-phenoxyquinolinyl analogues, which led to the very potent compound 3s. Activity was further enhanced by addition of a fluorine atom adjacent to the phenolic hydroxyl group as in 3w, 3z, 3aa, and 3bb to strengthen a key hydrogen bond. It is also shown that physical properties of the compounds can be modulated by variation of solvent-exposed substituents. Several of the compounds are likely the most potent known MIF tautomerase inhibitors; the most active ones are more than 1000-fold more active than the well-studied (R)-ISO-1 and more than 200-fold more active than the chromen-4-one Orita-13. Design, synthesis, and protein crystallography of biaryltriazoles as potent tautomerase inhibitors of macrophage migration inhibitory factor.,Dziedzic P, Cisneros JA, Robertson MJ, Hare AA, Danford NE, Baxter RH, Jorgensen WL J Am Chem Soc. 2015 Mar 4;137(8):2996-3003. doi: 10.1021/ja512112j. Epub 2015 Feb, 20. PMID:25697265[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||